论文部分内容阅读
2012年引起中东呼吸综合征的新型冠状病毒hCoVEMC,与2003年引起广东暴发性流行的严重急性呼吸综合征的SARS-CoV同属于β群冠状病毒,两种病毒存在许多相似之处[1-2]。研究表明SARS-CoV核衣壳蛋白(SARS-CoV N蛋白)可诱导产生强烈的体液和细胞免疫,是主要的抗原分子[3]和临床诊断的最佳靶标[4]。获得重组SARS-CoV N蛋白,是进一步研究SARS-CoV、hCoV-EMC以及其他可能出现的新型人冠状病毒N蛋白之间关系的前提。本文将目前研究
SARS-CoV, a new coronavirus that caused Middle East respiratory syndrome in 2012 and SARS-CoV that caused severe outbreak of SARS in Guangdong in 2003 belong to β-coronavirus. There are many similarities between the two viruses [1-2 ]. Studies have shown that the SARS-CoV nucleocapsid protein (SARS-CoV N protein) can induce strong humoral and cellular immunity and is the main antigen molecule [3] and the best target for clinical diagnosis [4]. Obtaining recombinant SARS-CoV N protein is a prerequisite for further study on the relationship between SARS-CoV, hCoV-EMC and other possible novel human coronavirus N proteins. This article will be the current study